Supriya Life targets 1-2% global mkt share with oral cancer detection kit

Quickblue is designed to detect oral cancer swiftly, eliminating the need for extensive preclinical and clinical trials

Supriya Lifescience
Supriya Lifescience
Anjali Singh Mumbai
2 min read Last Updated : Oct 23 2023 | 4:28 PM IST
Mumbai-based API manufacturing company Supriya Lifescience announced on Monday that it has partnered with Kalinga Institute of Industrial Technology (KIIT), Bhubaneswar, to develop Quickblue, an oral cancer detection kit in India. With this, Supriya Lifescience aims to capture a one to two per cent market share of the global cancer market.

Quickblue is designed to detect oral cancer swiftly, eliminating the need for extensive preclinical and clinical trials. This development aligns with Supriya Lifescience's vision of producing specialised products and becoming a global Contract Development and Manufacturing Organisation (CDMO) player.

This oral cancer detection kit offers a faster alternative to existing conventional methods, such as biopsies, and aims to be both more cost-effective and sensitive. With the global cancer market estimated at $21.5 billion, Supriya Lifescience aspires to capture a one to two per cent market share.

Satish Wagh, chairman of Supriya Lifescience, stated, "Quickblue could significantly reduce the cost of oral cancer detection by eliminating the need for multiple biopsies in cases of non-healing oral ulcers. This product is particularly relevant in India and the Asian subcontinent, where a significant proportion of oral cancer patients are found."

Wagh further added, "The development of an oral cancer detection kit aligns with Supriya Lifescience’s vision of manufacturing specialised products to meet unmet medical needs. This initiative represents a step toward diversifying the product portfolio of Supriya Lifescience. The company aims to expand and scale to new heights over the next decade."

Saloni Wagh , Director, Supriya Lifescience stated “We expect the Quickblue oral cancer detection kit to be commercially available in the next 3 years. And after its launch we anticipate to capture the global cancer market share up to 1 or 2 percent in the next 1 year.”

Commenting on the development of Quickblue, Mrutyunjay Suar, director general of Research and Development and Innovation at Kalinga Institute of Industrial Technology University, stated, "We are extremely proud to be part of this collaboration with Supriya Lifescience for such a novel product. Our teams of scholars and faculty members worked diligently with the expert team at Supriya Lifescience to develop this product. We believe this product can be a lifesaver through early detection of oral cancer."


*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Supriya Lifesciencemanufacturing Oral cancer

First Published: Oct 23 2023 | 3:35 PM IST

Next Story